Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study

OBJECTIVE: SELECTED, an open-label extension study, evaluated daclizumab beta treatment for up to 6 years in participants with relapsing multiple sclerosis who completed the randomized SELECT/SELECTION studies. We report final results of SELECTED. METHODS: Eligible participants who completed 1–2 yea...

Descripción completa

Detalles Bibliográficos
Autores principales: Gold, Ralf, Radue, Ernst-Wilhelm, Giovannoni, Gavin, Selmaj, Krzysztof, Havrdova, Eva Kubala, Montalban, Xavier, Stefoski, Dusan, Sprenger, Till, Robinson, Randy R., Fam, Sami, Smith, Jonathan, Chalkias, Spyros, Giannattasio, Giorgio, Lima, Gabriel, Castro-Borrero, Wanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501126/
https://www.ncbi.nlm.nih.gov/pubmed/32451615
http://dx.doi.org/10.1007/s00415-020-09835-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501126/
https://www.ncbi.nlm.nih.gov/pubmed/32451615
http://dx.doi.org/10.1007/s00415-020-09835-y

Ejemplares similares